Therapeutic potential of target of rapamycin inhibitors - PubMed (original) (raw)
Review
Therapeutic potential of target of rapamycin inhibitors
John B Easton et al. Expert Opin Ther Targets. 2004 Dec.
Abstract
Target of rapamycin (TOR) functions within the cell as a transducer of information from various sources, including growth factors, energy sensors, and hypoxia sensors, as well as components of the cell regulating growth and division. Blocking TOR function mimics amino acid, and to some extent, growth factor deprivation and has a cytostatic effect on proliferating cells in vivo. Inhibition of TOR in vivo, utilising its namesake rapamycin, leads to immunosuppression. This property has been exploited successfully with the use of rapamycin and its derivatives as a therapeutic agent in the prevention of organ rejection after transplantation with relatively mild side effects when compared to other immunosuppressive agents. The cytostatic effect of TOR on vascular smooth muscle cell proliferation has also recently been exploited in the therapeutic application of rapamycin to drug eluting stents for angioplasty. These stents significantly reduce the amount of arterial reblockage that results from proliferating vascular smooth muscle cells. In cancer, the effect of blocking TOR function on tumour growth and disease progression is currently of major interest and is the basis for a number of ongoing clinical trials. However, different cell types and tumours respond differently to TOR inhibition, and TOR is clearly not cytostatic for all types of cancer cells in vitro or in vivo. As the molecular details of how TOR functions and the targets of TOR activity are further elucidated, tumour and tissue specific functions are being identified that implicate TOR in angiogenesis, apoptosis, and the reversal of some forms of cellular transformation. This review will describe our current understanding of TOR function, describe the current strategies for employing TOR inhibitors in clinical and preclinical development, and outline future strategies for appropriate targets of TOR inhibitors in the treatment of disease.
Similar articles
- Clinical development of mammalian target of rapamycin inhibitors.
Dancey JE. Dancey JE. Hematol Oncol Clin North Am. 2002 Oct;16(5):1101-14. doi: 10.1016/s0889-8588(02)00051-5. Hematol Oncol Clin North Am. 2002. PMID: 12512385 Review. - Sirolimus, the first mTOR inhibitor.
Sánchez-Plumed JA, González Molina M, Alonso A, Arias M. Sánchez-Plumed JA, et al. Nefrologia. 2006;26 Suppl 2:21-32. Nefrologia. 2006. PMID: 17937632 Review. English, Spanish. No abstract available. - Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL. Cloughesy TF, et al. PLoS Med. 2008 Jan 22;5(1):e8. doi: 10.1371/journal.pmed.0050008. PLoS Med. 2008. PMID: 18215105 Free PMC article. Clinical Trial. - Current status and challenges associated with targeting mTOR for cancer therapy.
Dowling RJ, Pollak M, Sonenberg N. Dowling RJ, et al. BioDrugs. 2009;23(2):77-91. doi: 10.2165/00063030-200923020-00002. BioDrugs. 2009. PMID: 19489650 Review. - mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V. Wacheck V. Pharmacogenomics. 2010 Sep;11(9):1189-91. doi: 10.2217/pgs.10.113. Pharmacogenomics. 2010. PMID: 20860456 No abstract available.
Cited by
- Evaluation of Anticancer Efficacy of D-α-Tocopheryl Polyethylene-Glycol Succinate and Soluplus® Mixed Micelles Loaded with Olaparib and Rapamycin Against Ovarian Cancer.
Shin YB, Choi JY, Yoon MS, Yoo MK, Shin DH, Lee JW. Shin YB, et al. Int J Nanomedicine. 2024 Aug 2;19:7871-7893. doi: 10.2147/IJN.S468935. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39114180 Free PMC article. - Efficacy and Safety of Dual Paclitaxel and Sirolimus Nanoparticle-Coated Balloon.
Kawai K, Rahman MT, Nowicki R, Kolodgie FD, Sakamoto A, Kawakami R, Konishi T, Virmani R, Labhasetwar V, Finn AV. Kawai K, et al. JACC Basic Transl Sci. 2024 May 1;9(6):774-789. doi: 10.1016/j.jacbts.2024.02.002. eCollection 2024 Jun. JACC Basic Transl Sci. 2024. PMID: 39070273 Free PMC article. - A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer.
Meng D, Zhao X, Yang YC, Navickas A, Helland C, Goodarzi H, Singh M, Bandyopadhyay S. Meng D, et al. Oncogene. 2023 Jul;42(28):2207-2217. doi: 10.1038/s41388-023-02737-z. Epub 2023 Jun 1. Oncogene. 2023. PMID: 37264081 Free PMC article. - Methylomic correlates of autophagy activity in cystic fibrosis.
Caution K, Pan A, Krause K, Badr A, Hamilton K, Vaidya A, Gosu H, Daily K, Estfanous S, Gavrilin MA, Drew ME, Cormet-Boyaka E, Chen X, Frankhouser DE, Bundschuh R, Yan P, Dakhlallah D, Amer AO. Caution K, et al. J Cyst Fibros. 2019 Jul;18(4):491-500. doi: 10.1016/j.jcf.2019.01.011. Epub 2019 Feb 6. J Cyst Fibros. 2019. PMID: 30737168 Free PMC article. - The Enigma of Rapamycin Dosage.
Mukhopadhyay S, Frias MA, Chatterjee A, Yellen P, Foster DA. Mukhopadhyay S, et al. Mol Cancer Ther. 2016 Mar;15(3):347-53. doi: 10.1158/1535-7163.MCT-15-0720. Epub 2016 Feb 25. Mol Cancer Ther. 2016. PMID: 26916116 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous